|PhaseRx Inc -- USA Stock|| |
USD 0.28 0.0194 6.47%
Dr. Pat S. Stayton, Ph.D., is a CoFounder of PhaseRx, Inc. Dr. Stayton currently serves as the Washington Research Foundation Professor in the Department of Bioengineering at the University of Washington. He received his BS in Biology from Illinois State University in 1984, his PhD in Biochemistry from the University of Illinois in 1989, and was a Postdoctoral Research Associate at the Beckman Institute for Advanced Science and Technology, also at the University of Illinois
Stayton was elected as a Fellow of the American Institute for Medical and Biological Engineering and was the Director of the Center for Intracellular Delivery of Biologics, and his eclectic research group works at the interface of fundamental molecular science and applied molecular bioengineering. The group has projects aimed at elucidating basic principles underlying biomolecular recognition and connected projects applying those principles to drug delivery and diagnostic technologies through the development of new biohybrid materials that merge the impressive recognition and biofunctional properties of biomolecules with the impressive responsiveness and chemical versatility of "smart" polymers. The group has published over 200 research papers and was funded by the NIH, the NSF, NASA, The Bill and Melinda Gates Foundation, and by the Coulter Foundation.
The company has return on total asset (ROA)
of (64.2) %
which means that it has lost $64.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (228.17) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 5.44 M in liabilities with Debt to Equity (D/E) ratio of 264.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PhaseRx Inc has Current Ratio of 2.1 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. On December 11, 2017, PhaseRx, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. PhaseRx operates under Biotechnology classification in USA and traded on BATS Exchange exchange. It employs 10 people.PhaseRx Inc (PZRX) is traded on BATS Exchange in USA. It is located in WASHINGTON, U.S.A and employs 10 people. PhaseRx is listed under Pharmaceutical Products category by Fama And French industry classification.